Dexmedetomidine Ameliorates Myocardial Ischemia‐Reperfusion Injury by Inhibiting MDH2 Lactylation via Regulating Metabolic Reprogramming

Dexmedetomidine Ameliorates Myocardial Ischemia‐Reperfusion Injury by Inhibiting MDH2 Lactylation via Regulating Metabolic Reprogramming

Abstract Myocardial ischemia‐reperfusion injury (MIRI) significantly worsens the outcomes of patients with cardiovascular diseases. Dexmedetomidine (Dex) is recognized for its cardioprotective properties, but the related mechanisms, especially regarding metabolic reprogramming, have not been fully c...

Full description

Saved in:
Bibliographic Details
Main Authors: Han She, Yi Hu, Guozhi Zhao, Yunxia Du, Yinyu Wu, Wei Chen, Yong Li, Yi Wang, Lei Tan, Yuanqun Zhou, Jie Zheng, Qinghui Li, Hong Yan, Qingxiang Mao, Deyu Zuo, Liangming Liu, Tao Li
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Advanced Science
Subjects:
dexmedetomidine
ferroptosis
lactylation
metabolic reprogramming
myocardial ischemia‐reperfusion injury
Online Access:https://doi.org/10.1002/advs.202409499
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items